Business Context and Reporting Period
Fresenius Medical Care AG & Co. KGaA, a German-based foreign private issuer, filed Form 6-K on October 29, 2020. The filing serves to distribute a press release announcing third-quarter financial results for the period ended September 30, 2020.
Key Financial Metrics
The provided text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The filing references the inclusion of these figures in attached Exhibits 99.1 (Press Release) and 99.2 (Financial Figures).
The company utilizes the following non-GAAP financial measures to supplement IFRS reporting:
- EBITDA (Operating income excluding interest, taxes, depreciation, and amortization)
- Delivered operating income (Earnings before interest and taxes)
- Free cash flow
- Net leverage ratio (Net debt to adjusted EBITDA)
- Results presented in constant currency
Material Changes
The filing text does not provide specific data regarding material changes versus the prior comparable period. Investors must refer to the attached press release and financial exhibits for comparative analysis.
Guidance, Outlook, and Risks
The text states that non-GAAP measures are provided to enhance understanding of current performance and future prospects. However, the filing explicitly notes that these measures should not be used as a substitute for GAAP/IFRS financial measures. No specific guidance, management commentary, risks, or contingencies are detailed within the Form 6-K cover text itself.
Investor Verification Checklist
- Verify specific Q3 2020 revenue and profit figures in Exhibit 99.2.
- Review the reconciliation of non-GAAP measures (EBITDA, Free Cash Flow) to IFRS standards in the attached press release.
- Confirm the net leverage ratio and liquidity position as detailed in the exhibits.
- Assess the impact of constant currency adjustments on reported results.